Currently, 23% of US households have someone using GLP-1 medications annually, Chicago-based Circana estimated, noting the percentage correlates to an underlying individual usage rate of 10% to 14%
10.1530/JOE-23-0342 J Endocrinol
To learn more about this topic and how TRISTAR can support your claims management needs, contact us at [email protected]
Injection site reactions occur in a minority of users, manifesting as redness, swelling, or temporary discomfort at the administration location
Over a 16-week protocol, that is less than 20 minutes of total documentation time in exchange for a complete, analyzable record of your research
No one can lawfully sell retatrutide for human administration or compound it under U.S